Presence of serum RalA and serum p53 autoantibodies in 1833 patients with various types of cancers.
Autoantibody
Esophageal cancer
Hepatocellular carcinoma
RalA
p53
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
05
08
2021
accepted:
29
09
2021
pubmed:
12
10
2021
medline:
8
1
2022
entrez:
11
10
2021
Statut:
ppublish
Résumé
RalA is a member of the Ras superfamily of small GTPases. The Anti-RalA autoantibodies (s-RalA-Abs) act as tumor markers in various types of cancer and are negatively associated with the p53 autoantibodies (s-p53-Abs). This study aimed to evaluate the relationship between s-RalA-Abs and s-p53-Abs in various types of cancer. A total of 1833 cancer patients (esophageal cancer, 172; hepatocellular carcinoma, 91; lung cancer, 269; gastric cancer, 317; colon cancer, 262; breast cancer, 364; and prostate cancer, 358) and 73 healthy subjects were enrolled in the study. The levels of s-RalA-Abs and s-p53-Abs were analyzed using enzyme-linked immunosorbent assay, and the positivity rates and relations between the two autoantibodies were evaluated. The cutoff values for s-RalA abs and s-p53 abs were set as mean + 2 standard deviation and the values higher than the cutoff values were defined as positive. The titers in all cancer types were significantly higher than those in the controls (P < 0.01). The positivity rates for s-RalA-Abs ranged between 11.7 and 21.5%, and those for s-p53-Abs ranged between 12 and 28.5%. A combined assay of the two antibodies revealed positivity rates of 20.9 and 44.2%. In Stage 0/I/II tumors, the positivity rates of the combination of the two antibodies ranged between 21.5 and 42.3%. The two autoantibodies were complementary to each other in the prostate and breast cancers, but independent in other carcinomas. The combined use of s-RalA-Abs and s-p53-Abs tended to increase the positivity rate in all cancers, including Stage 0/I/II cancers.
Sections du résumé
BACKGROUND
BACKGROUND
RalA is a member of the Ras superfamily of small GTPases. The Anti-RalA autoantibodies (s-RalA-Abs) act as tumor markers in various types of cancer and are negatively associated with the p53 autoantibodies (s-p53-Abs). This study aimed to evaluate the relationship between s-RalA-Abs and s-p53-Abs in various types of cancer.
METHODS
METHODS
A total of 1833 cancer patients (esophageal cancer, 172; hepatocellular carcinoma, 91; lung cancer, 269; gastric cancer, 317; colon cancer, 262; breast cancer, 364; and prostate cancer, 358) and 73 healthy subjects were enrolled in the study. The levels of s-RalA-Abs and s-p53-Abs were analyzed using enzyme-linked immunosorbent assay, and the positivity rates and relations between the two autoantibodies were evaluated. The cutoff values for s-RalA abs and s-p53 abs were set as mean + 2 standard deviation and the values higher than the cutoff values were defined as positive.
RESULTS
RESULTS
The titers in all cancer types were significantly higher than those in the controls (P < 0.01). The positivity rates for s-RalA-Abs ranged between 11.7 and 21.5%, and those for s-p53-Abs ranged between 12 and 28.5%. A combined assay of the two antibodies revealed positivity rates of 20.9 and 44.2%. In Stage 0/I/II tumors, the positivity rates of the combination of the two antibodies ranged between 21.5 and 42.3%. The two autoantibodies were complementary to each other in the prostate and breast cancers, but independent in other carcinomas.
CONCLUSION
CONCLUSIONS
The combined use of s-RalA-Abs and s-p53-Abs tended to increase the positivity rate in all cancers, including Stage 0/I/II cancers.
Identifiants
pubmed: 34632560
doi: 10.1007/s10147-021-02045-0
pii: 10.1007/s10147-021-02045-0
doi:
Substances chimiques
Autoantibodies
0
Biomarkers, Tumor
0
Tumor Suppressor Protein p53
0
RALA protein, human
EC 3.6.1.-
ral GTP-Binding Proteins
EC 3.6.5.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
72-76Informations de copyright
© 2021. Japan Society of Clinical Oncology.
Références
Gentry LR, Martin TD, Reiner DJ, et al (2014) Ral small GTPase signaling and oncogenesis: More than just 15 minutes of fame. Biochim Biophys Acta 1843:2976–2988
doi: 10.1016/j.bbamcr.2014.09.004
Shimada H (2018) p53 molecular approach to diagnosis and treatment of esophageal squamous cell carcinoma. Ann Gastroenterol Surg 13:266–273
doi: 10.1002/ags3.12179
Nanami T, Shimada H, Yajima S et al (2016) Clinical significance of serum autoantibodies against Ras-like GTPases, RalA, in patients with esophageal squamous cell carcinoma. Esophagus 13:167–172
doi: 10.1007/s10388-015-0510-8
Nanami T, Hoshino I, Ito M et al (2020) Prevalence of autoantibodies against Ras-like GTPases, RalA, in patients with gastric cancer. Mol Clin Oncol. https://doi.org/10.3892/mco.2020.2098
doi: 10.3892/mco.2020.2098
pubmed: 32765875
pmcid: 7403843
Ushigome M, Nabeya Y, Soda H et al (2018) Multi-panel assay of serum autoantibodies in colorectal cancer. Int J Clin Oncol 23:917–923
doi: 10.1007/s10147-018-1278-3
Okada R, Otsuka Y, Wakabayashi T et al (2020) Six autoantibodies as potential serum biomarkers of hepatocellular carcinoma: a prospective multicenter study. Int J Cancer. https://doi.org/10.1002/ijc.33165
doi: 10.1002/ijc.33165
pubmed: 32818320
Kubota Y, Ogata H, Otsuka S et al (2017) Presence of autoantibodies against Ras-like GTPases in serum in stage I/II breast cancer. Toho J Med 3:125–130
Hoshino I, Nagata M, Takiguchi N et al (2017) Panel of autoantibodies against multiple tumor-associated antigens for detecting gastric cancer. Cancer Sci 108:308–315
doi: 10.1111/cas.13158
Wang T, Liu H, Pei L, et al (2020) Screening of tumor-associated antigens based on Oncomine database and evaluation of diagnostic value of autoantibodies in lung cancer. Clin Immunol 210:108262
doi: 10.1016/j.clim.2019.108262
Suzuki T, Yajima S, Okamura A et al (2021) Clinical impact of preoperative serum p53 antibody titers in 1487 patients with surgically treated esophageal squamous cell carcinoma: a multi-institutional study. Esophagus 18:65–71
doi: 10.1007/s10388-020-00761-6
Oshima Y, Suzuki T, Yajima S et al (2020) Serum p53 antibody: useful for detecting gastric cancer but not for predicting prognosis after surgery. Surg Today 50:1402–1408
doi: 10.1007/s00595-020-02030-6
Okada R, Shimada H, Otsuka Y et al (2017) Serum p53 antibody as a potential tumor marker in extrahepatic cholangiocarcinoma. Surg Today 47:1492–1499
doi: 10.1007/s00595-017-1540-8
Tecleab A, Zhang X, Sebti SM (2014) Ral GTPase down-regulation stabilizes and reactivates p53 to inhibit malignant transformation. J Biol Chem 289:31296–31309
doi: 10.1074/jbc.M114.565796
Kanda Y (2013) Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 48:452–458
doi: 10.1038/bmt.2012.244